Latest News-Ascentage Pharma Mediaroom_Page

Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia

SUZHOU, China, and ROCKVILLE, MD., Nov. 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-11-22 21:24 1821

Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in Metastatic ER+/HER2- Breast Cancer

SUZHOU, China, and ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-11-08 21:47 2195

ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response

SUZHOU, China, and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-11-05 09:05 3226

ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting

SUZHOU, China and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-11-05 08:43 2383

The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics

SUZHOU, China, and ROCKVILLE, Md., Oct. 18, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-10-18 22:42 2855

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

SUZHOU, China, and ROCKVILLE, MD, Sept 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-09-23 07:40 1730

WCLC 2021 | Mini Oral - Ascentage Pharma Announces Latest Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Small Cell Lung Cancer

SUZHOU, China, and ROCKVILLE, MD., Sept 9, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-09-09 08:26 5495

Ascentage Pharma Announces 2021 Interim Results Highlighting the Potential of Its Core Drug Candidates and Major Breakthroughs in Strategic Collaborations

SUZHOU, China, and ROCKVILLE, Md., Aug. 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glo...

2021-08-24 19:06 3063

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

SUZHOU, China, and ROCKVILLE, Md., July 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-07-29 07:40 3860

Ascentage Pharma's MDM2-p53 Inhibitor APG-115 (Alrizomadlin) Granted an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma, Marking the Twelfth Obtained by the Company

SUZHOU, China and ROCKVILLE, Md., July 21, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-07-21 18:37 4074

Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax

SUZHOU, China, and ROCKVILLE, Md., July 19, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-07-19 18:41 3412

Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling US$245 Million Including Commercialization of Olverembatinib (HQP1351) in China, Joint Clinical Development of Lisaftoclax (APG-2575) and Equity Investment

SUZHOU, China, and ROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-07-15 01:43 5550

Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors

SUZHOU, China, and ROCKVILLE, Md., June 15, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-06-15 07:39 16609

Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL

SUZHOU, China, and ROCKVILLE, MD, June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-06-08 07:30 4805

Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs

SUZHOU, China, and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-06-08 07:21 11598

ASCO 2021 | Ascentage Pharma to Announce Updated Data of Lisaftoclax (APG-2575) Demonstrating an ORR of Around 80% and Therapeutic Potential in Patients with R/R CLL/SLL in Oral Presentation

SUZHOU, China and ROCKVILLE, Md., May 20, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-05-20 08:44 4667

ASCO 2021 | Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation

SUZHOU, China and ROCKVILLE, Md., May 20, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-05-20 08:17 5028

Ascentage Pharma (6855.HK) Becomes a Constituent of MSCI China Small Cap Index

SUZHOU, China and ROCKVILLE, Md., May 13, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-05-13 08:28 2076

Ascentage Pharma to Announce Results from Four Clinical Studies at 2021 ASCO Annual Meeting, with Data of Its Drug Candidates Including Lisaftoclax (APG-2575) to Be Released in Oral Presentations for the First Time

SUZHOU, China and ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-04-21 08:38 2617

Ascentage Pharma Releases Preclinical Data of Its Core Drug Candidates at AACR Annual Meeting 2021, with Results Signifying the Potential of Multiple Combination Therapies in Cancer

SUZHOU, China and ROCKVILLE, Md., April 13, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-04-13 08:28 2331